Molecular basis for targeting Caveolin-1 in multiple myeloma therapy.

[INTRODUCTION] Multiple myeloma (MM) is a plasma cell malignancy characterized by frequent relapse and resistance to therapy. Caveolin-1 (Cav-1), a scaffolding protein that forms plasma membrane caveolae, has been demonstrated to regulate key processes including cell signaling, metabolism, autophagy, and interactions with the bone marrow microenvironment.

[AREAS COVERED] This review outlines Cav-1's role in MM progression and therapy resistance, including its effects on cell survival, adhesion, and communication with the bone marrow environment. Preclinical approaches to target Cav-1, such as small molecules, peptides, RNA-based methods, CRISPR, and tumor-specific delivery, are summarized, including combination with proteasome inhibitors. Challenges for clinical translation, such as the lack of selective inhibitors and possible toxicity, are also discussed.

[EXPERT OPINION] Cav-1 is a context-dependent therapeutic vulnerability in MM. Blocking Cav-1 can restore drug sensitivity, reduce protection from the bone marrow environment, and improve immune killing of tumor cells. Given the multifaceted nature of Cav-1 and its prevalence in normal tissues, the development of selective or tumor-targeted delivery mechanisms is imperative. New strategies, including inhibitors and nanoparticle delivery, combined with biomarker-guided patient selection, may offer safe and effective targeting of Cav-1 and support combination treatments for resistant MM.